INSM

Insmed Incorporated [INSM] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

INSM Stock Summary

Top 10 Correlated ETFs

INSM

Top 10 Correlated Stocks

INSM

In the News

INSM Financial details

Company Rating
-
Market Cap
4.05B
Income
-749.57M
Revenue
305.21M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
912
Optionable
No
Shortable
Yes
Earnings
02 May 2024
P/E
-5.34
Forward P/E
-
PEG
-1.46
P/S
13.46
P/B
-12.07
P/C
-
P/FCF
-7.47
Quick Ratio
3.64
Current Ratio
4.12
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-5.34
EPS next Y
-
EPS next Q
-
EPS this Y
36.57%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
12.15%
Revenue last 5Y
17.47%
Revenue Q/Q
5.84%
EPS Q/Q
15.32%
-
-
-
-
SMA20
-
SMA50
6.94%
SMA100
10%
Inst Own
-
Inst Trans
-
ROA
-56%
ROE
365%
ROC
-0.65%
Gross Margin
79%
Oper. Margin
-236%
Profit Margin
-246%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
16.46-32.0
52W High
+127.13%
52W Low
+354.25%
RSI
38
Rel Volume
1.13
Avg Volume
1.63M
Volume
1.84M
Perf Week
-7.46%
Perf Month
-13.07%
Perf Quarter
3.89%
Perf Half Y
0.28%
-
-
-
-
Beta
0.915
-
-
Volatility
1.71%, 2.2%
Prev Close
-4.73%
Price
72.68
Change
-4.67%

Something similar

Top by Market Cap
NVD.DE
FXAIX
VTSAX
APC.DE
BRH.DE
Top Correlated ETFs
WXM.TO
PXI
MEDI
PTH
UTES
Top Correlated Stocks
TVTX
MIR
VNOM
FTHM
APO-PA
Similar Market Cap
2484.TW
6055.HK
601789.SS
1471.TW
STORY-B.ST

Company Profile

Healthcare Biotechnology
  • Volume Average 1.63M
  • Market Capitalization 4.05B
  • Employee 912
  • CEO Mr. William H. Lewis J.D., M.B.A.
  • Headquarters Bridgewater,NJ,US
  • IPO Date 2000-06-01
  • Website https://www.insmed.com

Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders. Insmed Incorporated was founded in 1988 and is headquartered in Bridgewater, New Jersey.